Second-Line Irinotecan after Cisplatin, Fluoropyrimidin and Docetaxel for Chemotherapy of Metastatic Gastric Cancer

  • Kucukzeybek, Yuksel (Medical Oncology Clinic, Izmir Ataturk Training and Research Hospital) ;
  • Dirican, Ahmet (Medical Oncology Clinic, Izmir Ataturk Training and Research Hospital) ;
  • Erten, Cigdem (Medical Oncology Clinic, Izmir Ataturk Training and Research Hospital) ;
  • Somali, Isil (Medical Oncology Clinic, Izmir Ataturk Training and Research Hospital) ;
  • Can, Alper (Medical Oncology Clinic, Izmir Ataturk Training and Research Hospital) ;
  • Demir, Lutfiye (Medical Oncology Clinic, Izmir Ataturk Training and Research Hospital) ;
  • Bayoglu, Ibrahim Vedat (Medical Oncology Clinic, Izmir Ataturk Training and Research Hospital) ;
  • Akyol, Murat (Medical Oncology Clinic, Izmir Ataturk Training and Research Hospital) ;
  • Medeni, Murat (Internal Medicine, Izmir Ataturk Training and Research Hospital) ;
  • Tarhan, Mustafa Oktay (Medical Oncology Clinic, Izmir Ataturk Training and Research Hospital)
  • Published : 2012.06.30


Aim: Tumors of upper gastrointestinal tract are among the cancers that have a quite lethal course. Cytotoxic chemotherapy is the most efficient therapeutic modality for metastatic gastric cancer. In patients who do not respond to first-line treatment, the response rate to second-line therapies is generally low and the toxicity rates high. This study concerned the efficacy and the side effect profile of second-line therapy with irinotecan in the patients who were being followed-up with the diagnosis of metastatic gastric cancer in $\dot{I}$zmir, Turkey. Materials and Methods: We retrospectively evaluated the efficacy and toxicity in 31 patients with metastatic gastric adenocarcinoma who presented to the polyclinic of Medical Oncology of Izmir Ataturk Education and Research Hospital between May 2008 and July 2011. All received chemotherapy regimens containing cisplatin, fluoropyrimidine (5-FU) and docetaxel as the first-line therapy for late stage disease. Irinotecan as a single agent was given at a dose of 210 mg/$m^2$ on each 21 days. Irinotecan (180 mg/$m^2$ on day 1), 5-FU (500 mg/$m^2$ on days 1-2) and leucovorin (LV; 60 mg/$m^2$ on days 1-2) as a combined regimen were given over a 14 day period. Results: Median age was 54 (range, 31-70). Irinotecan was given as a combined regimen for median 6 cycles (range, 3-12) and as a single agent for median 3 cycles (range, 1-10). Metastases were detected in one site in six patients (19%), in two different sites in 17 patients (55%) and in three or more sites in eight patients (26%). Four patients (12.9%) showed partial response and six patients (19.3%) showed stable disease. Progression-free survival (PFS) was found to be 3.26 months (95% CI, 2.3-4.2). Median overall survival (OS) was found to be 8.76 months (95% CI, 4.5-12.9). The most commonly seen grade 3/4 side effect was neutropenia but the the therapy was generally well-tolerated. Conclusions: In this study, it was demonstrated that second-line therapy with irinotecan given following the first-line therapy with cisplatin, fluoropyrimidine (5-FU) and docetaxel was efficient and safe. Further studies are needed for confirmation.


  1. Baize N, Abakar-Mahamat A, Mounier N, Berthier F, Caroli- Bosc FX (2009). Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens. Cancer Chemother Pharmacol, 64, 549.
  2. Cho BC, Kim JH, Kim CB, et al (2006). Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer. Oncol Rep, 15, 621.
  3. Chun JH, Kim HK, Lee JS, et al (2004). Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy. Jpn J Clin Oncol, 34, 8.
  4. Eisenhauer EA, Therasse P, Bogaerts J, et al (2009). J New response evaluation criteria in solid tumours: revised RECIST guideline (version 1. 1). Eur J Cancer, 45, 228.
  5. Giuliani F, Gebbia V, De Vita F, et al (2003). Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G. O. I. M.). Anticancer Res, 23, 4219.
  6. Graziano F, Catalano V, Baldelli AM, et al (2000). A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. Ann Oncol, 11, 1263.
  7. Jeong J, Jeung HC, Rha SY, et al (2008). Phase II study of combination chemotherapy of 5-fluorouracil, low-dose leucovorin, and oxaliplatin (FLOX regimen) in pretreated advanced gastric cancer. Ann Oncol, 19, 1135.
  8. Kim SH, Lee GW, Go SI, et al (2010). A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen. Am J Clin Oncol, 33, 572-6.
  9. Kodera Y, Ito S, Mochizuki Y, et al (2007) A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric Cancer (CCOG0302 study). Anticancer Res, 27, 2667.
  10. Murad AM, Santiago FF, Petroianu, et al (1993). Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer, 72, 37-41.<37::AID-CNCR2820720109>3.0.CO;2-P
  11. Park S, Lim D, Park K, et al (2011). A multicenter, randomized trial comparing second-line chemotherapy plus best supportive care (BSC) with BSC alone for pretreated advanced gastric cancer (AGC) (Abstract 4004). J Clin Oncol, 29, 257.
  12. SEER Cancer Statistics http://www. seer. cancer. gov/statistics/ (Accessed on March 31, 2011).
  13. Seo HY, Kim DS, Choi YS, et al (2009). Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis. Cancer Chemother Pharmacol, 63, 433.
  14. Sym SJ, Ryu MH, Lee JL, et al (2008). Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane. Am J Clin Oncol, 31, 151.
  15. Therasse P, Arbuck SG, Eisenhauer EA, et al (2000). New guidelines to evaluate the response to treatment in solid tumors: European Organization for . Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst, 92, 205.
  16. Thuss-Patience PC, Kretzschmar A, Bichev D, et al (2011). Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer-a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer, 47, 2306-14.

Cited by

  1. ) and Paclitaxel for Treatment of Patients with Metastatic Gastric Cancer vol.14, pp.4, 2013,
  2. Efficacy and Safety of Docetaxel or Epirubicin, Combined with Cisplatin and Fluorouracil, (DCF and ECF) Regimens as First Line Chemotherapy for Advanced Gastric Cancer: a Retrospective Analysis from Turkey vol.15, pp.16, 2014,
  3. Safety and continuity of second- and third-line therapy with paclitaxel or irinotecan for advanced and recurrent gastric cancer vol.2, pp.3, 2014,
  4. Cost-effectiveness and safety of ramucirumab plus paclitaxel chemotherapy in the treatment of advanced and recurrent gastric cancer pp.1477-092X, 2017,
  5. Biomarker-Driven Therapy in Metastatic Gastric and Esophageal Cancer: Real-Life Clinical Experience vol.13, pp.2, 2018,